Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia

Vaccine 2026 Open access

Read full text
Authors: Fiona Giannini, Alexandra B. Hogan, Christopher C. Blyth, Kathryn Glass, Hannah C Moore
DOI: 10.1016/j.vaccine.2026.128731
Cited by: 1
References: 48

Abstract

BACKGROUND: Two RSV immunisations products: a maternal vaccine, Abrysvo, and a long-acting monoclonal antibody, nirsevimab, both designed to prevent RSV illness in infants, have recently become available. Modelling evidence is required to inform how to optimally use these products in immunisation programs to reduce the burden of RSV in young children. METHODS: We extend a dynamic transmission model calibrated to RSV-hospitalisation data of children aged

Fields of Study & Subjects

Respiratory viral infections research Virology and Viral Diseases Animal Disease Management and Epidemiology

Publication details

Journal / source
Vaccine
Publisher
Elsevier BV
Volume
86
Pages
128731–128731
Publication date
23 May 2026
Language
EN